NASDAQ:CNTX Context Therapeutics Q4 2024 Earnings Results & Report $0.17 0.00 (-2.69%) Closing price 04:00 PM EasternExtended Trading$0.17 +0.00 (+0.96%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Context Therapeutics beat analyst earnings expectations in its Q4 2024 results, released March 20, 2025. The company reported EPS of -$0.04 versus the -$0.05 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 20, 2025TimeBefore Market OpensConference Call DateMarch 19, 2025Conference Call7:00 PM ET Context Therapeutics EPS ResultsActual EPS-$0.04Consensus EPS -$0.05Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersContext Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesReportAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsReportAnnual report(10-K) Context Therapeutics Q4 2024 Earnings FAQ Did Context Therapeutics beat earnings estimates for Q4 2024? Context Therapeutics (NASDAQ:CNTX) reported earnings of -$0.04 per share for Q4 2024, beating the consensus estimate of -$0.05. The report was announced on Thursday, March 20, 2025. Context Therapeutics Earnings HeadlinesContext Therapeutics Inc. (CNTX) - What Are Analysts Thinking About This Stock?November 13, 2026 | americanbankingnews.comContext Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10, 2026 | marketscreener.comMURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 18 at 1:00 AM | Paradigm Press (Ad)Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline ProgressNovember 10, 2026 | globenewswire.comCNTX Updates CT-95 Cancer Study as Trial Is Listed as TerminatedNovember 5, 2026 | tipranks.comContext Therapeutics (CNTX) Stock Forecast & Price TargetNovember 3, 2026 | tipranks.comSee More Context Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Context Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your email. Email Address About Context TherapeuticsContext Therapeutics (NASDAQ:CNTX) is a clinical-stage biopharmaceutical company developing treatments for solid tumors. The company’s research focuses on bispecific antibodies designed to direct immune cells toward cancer cells. Its pipeline includes CTIM-76, a T-cell-engaging bispecific antibody targeting claudin 6, a protein found on certain tumor cells. Context has also been developing CT-95, which targets mesothelin, another protein expressed by some solid tumors. Founded with an initial focus on therapies for women’s cancers, Context has since broadened its work to address a range of solid tumors. The company is based in the United States and conducts clinical-stage drug development.View Context Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Viking’s Low-Water Miss Looks Like a Buy-the-Dip OpportunityDisney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.